At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Funding will be specifically used to accelerate the clinical development of urcosimod (formerly called OK-101).

Pinguecula is a benign, common degeneration of the conjunctiva that appears as a grey-white-yellow mass on the bulbar ...

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other ...

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.

The US Food and Drug Administration (FDA) recently granted fast track designation to Sanofi’s SAR446597 for the treatment of ...

The US Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ...